Effector-Memory B-Lymphocytes and Follicular Helper T-Lymphocytes as Central Players in the Immune Response in Vaccinated and Nonvaccinated Populations against SARS-CoV-2
Por:
Islas-Vazquez, Lorenzo, Cruz-Aguilar, Marisa, Velazquez-Soto, Henry, Jimenez-Corona, Aida, Pérez-Tapia S.M., Jimenez-Martinez, Maria C.
Publicada:
1 oct 2022
Resumen:
Vaccines have been recognized as having a central role in controlling
the COVID-19 pandemic; however, most vaccine development research is
focused on IgG-induced antibodies. Here, we analyzed the generation of
IgGs related to SARS-CoV-2 and the changes in B- and T-lymphocyte
proportions following vaccination against COVID-19. We included samples
from 69 volunteers inoculated with the Pfizer-BioNTech (BNT162b2), Astra
Zeneca (AZD1222 Covishield), or Sputnik V (Gam-COVID-Vac) vaccines. IgGs
related to SARS-CoV-2 increased after the first vaccine dose compared
with the nonvaccinated group (Pfizer, p = 0.0001; Astra Zeneca, p <
0.0001; Sputnik V, p = 0.0089). The results of the flow cytometry
analysis of B- and T-lymphocytes showed a higher proportion of
effector-memory B-lymphocytes in both first and second doses when
compared with the nonvaccinated subjects. FcRL4+ cells were increased in
second-dose-vaccinated COVID-19(-) and recovered COVID-19(+)
participants when compared with the nonvaccinated participants.
COVID-19(-) participants showed a lower proportion of follicular helper
T-lymphocytes (TFH) in the second dose when compared with the
first-vaccine-dose and nonvaccinated subjects. In conclusion, after the
first vaccine dose, immunization against SARS-CoV-2 induces IgG
production, and this could be mediated by TFH and effector-memory
B-lymphocytes. Our data can be used in the design of vaccine schedules
to evaluate immuno-bridging from a cellular point of view.
Filiaciones:
Islas-Vazquez, Lorenzo:
Department of Immunology and Research Unit, Institute of Ophthalmology “Conde de Valenciana Foundation”, Mexico City, 06800, Mexico
Cruz-Aguilar, Marisa:
Department of Immunology and Research Unit, Institute of Ophthalmology “Conde de Valenciana Foundation”, Mexico City, 06800, Mexico
Velazquez-Soto, Henry:
Department of Immunology and Research Unit, Institute of Ophthalmology “Conde de Valenciana Foundation”, Mexico City, 06800, Mexico
Jimenez-Corona, Aida:
Department of Ocular Epidemiology, Institute of Ophthalmology “Conde de Valenciana Foundation”, Mexico City, 06800, Mexico
General Directorate of Epidemiology, Mexico City, 01480, Mexico
Pérez-Tapia S.M.:
Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, 11340, Mexico
Laboratorio Nacional para Servicios Especializados de Investigación, Desarrollo e Innovación (I+D+i) para Farmoquímicos y Biotecnológicos, LANSEIDI-FarBiotec-CONACyT, Mexico City, 11340, Mexico
Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (ENCB-IPN), Mexico City, 11340, Mexico
Jimenez-Martinez, Maria C.:
Department of Immunology and Research Unit, Institute of Ophthalmology “Conde de Valenciana Foundation”, Mexico City, 06800, Mexico
Department of Biochemistry, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, 04510, Mexico
gold, Green Published, Gold, Green
|